Elevated GnRH receptor expression plus GnRH agonist treatment inhibits the growth of a subset of papillomavirus 18-immortalized human prostate cells

Prostate

Volumn 71, Issue 9, 2011, Pages 915-928

  Morgan, Kevin ^a   Stavrou, Emmanouil ^a   Leighton, Samuel P ^a   Miller, Nicola ^a   Sellar, Robin ^a   Millar, Robert P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

actin cytoskeleton; agonist; anti proliferation; apoptosis; exosomes; GnRH receptor; inositol phosphate; mitogen activated protein kinases; prostate; signaling

Indexed keywords

3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; CALCIUM ION; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN AGONIST; GONADORELIN RECEPTOR; HOE 33342; INOSITOL PHOSPHATE; ITURELIX; MITOGEN ACTIVATED PROTEIN KINASE; TRIPTORELIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL GROWTH; CELL IMMORTALIZATION; CELL STRAIN DU145; CELL STRAIN HEK293; CELL STRAIN LNCAP; CELL STRAIN PC3; CELL SUBPOPULATION; ENZYME ACTIVATION; EXOSOME; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; MYOEPITHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE; SIGNAL TRANSDUCTION;

ALPHAPAPILLOMAVIRUS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL TRANSFORMATION, VIRAL; EXOSOMES; FLOW CYTOMETRY; GONADOTROPIN-RELEASING HORMONE; HUMANS; INOSITOL PHOSPHATES; MALE; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION; TRANSFECTION; TRIPTORELIN PAMOATE;

EID: 79955581160     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21308     Document Type: Article

References (68)

1. Wolfe AM, Wray S, Westphal H, Radovick S,. Cell-specific expression of the human gonadotropin-releasing hormone gene in transgenic animals. J Biol Chem 1996; 271: 20018-20023. (Pubitemid 26281750)
2. Jennes L, Eyigor O, Janovick JA, Conn PM,. Brain gonadotropin releasing hormone receptors: Localization and regulation. Recent Prog Horm Res 1997; 52: 475-490. (Pubitemid 127470222)
3. Granger A, NgÃ-Muller V, Bleux C, Guigon C, Pincas H, Magre S, Daegelen D, Tixier-Vidal A, Counis R, LaverriÃre JN,. The promoter of the rat gonadotropin-releasing hormone receptor gene directs the expression of the human placental alkaline phosphatase reporter gene in gonadotrope cells in the anterior pituitary gland as well as in multiple extrapituitary tissues. Endocrinology 2004; 145: 983-993. (Pubitemid 38183843)
4. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J,. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990; 62: 96-99. (Pubitemid 20226453)
5. Qayum A, Gullick WJ, Mellon K, Krausz T, Neal D, Sikora K, Waxman J,. The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 1990; 37: 899-902.
6. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG,. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2001; 163: 623-629.
7. Tieva A, Stattin P, Wikström P, Bergh A, Damber JE,. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001; 47: 276-284. (Pubitemid 32521747)
8. Straub B, Müller M, Krause H, Schrader M, Miller K,. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003; 62: 172-176. (Pubitemid 36802109)
9. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M,. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992; 75: 207-212.
10. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M,. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU145: Evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994; 54: 4091-4095. (Pubitemid 24258114)
11. Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G,. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate 2006; 66: 200-210. (Pubitemid 43191241)
12. White CD, Stewart AJ, Lu ZL, Millar RP, Morgan K,. Antiproliferative effects of GnRH agonists: Prospects and problems for cancer therapy. Neuroendocrinology 2008; 88: 67-79.
13. Ravenna L, Salvatori L, Morrone S, Lubrano C, Cardillo MR, Sciarra F, Frati L, Di Silverio F, Petrangeli E,. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl 2000; 21: 549-557. (Pubitemid 30437701)
14. Franklin J, Hislop J, Flynn A, McArdle CA,. Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. J Endocrinol 2003; 176: 275-284. (Pubitemid 36284820)
15. Kraus S, Levy G, Hanoch T, Naor Z, Seger R,. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 2004; 64: 5736-5744. (Pubitemid 39095572)
16. Enomoto M, Utsumi M, Park MK,. Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells. Endocrinology 2006; 147: 530-542. (Pubitemid 43004309)
17. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P,. Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab 2009; 94: 1761-1767.
18. Angelucci C, Lama G, Iacopino F, Ferracuti S, Bono AV, Millar RP, Sica G,. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 2009; 36: 87-97.
19. Kim DK, Yang JS, Maiti K, Hwang JI, Kim K, Seen D, Ahn Y, Lee C, Kang BC, Kwon HB, Cheon J, Seong JY,. A gonadotropin-releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 2009; 69: 923-931.
20. Miles LE, Hanyaloglu AC, Dromey JR, Pfleger KD, Eidne KA,. Gonadotropin-releasing hormone receptor-mediated growth suppression of immortalized LbetaT2 gonadotrope and stable HEK293 cell lines. Endocrinology 2004; 145: 194-204. (Pubitemid 38094516)
21. Lõpez de Maturana R, Pawson AJ, Lu ZL, Davidson L, Maudsley S, Morgan K, Langdon SP, Millar RP,. Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: Support for the concept of ligand-induced selective signaling. Mol Endocrinol 2008; 22: 1711-1722. (Pubitemid 351920402)
22. Morgan K, Stewart AJ, Miller N, Mullen P, Muir M, Dodds M, Medda F, Harrison D, Langdon S, Millar RP,. Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 2008; 68: 6331-6340.
23. White CD, Coetsee M, Morgan K, Flanagan CA, Millar RP, Lu ZL,. A crucial role for Galphaq/11, but not Galphai/o or Galphas, in gonadotropin-releasing hormone receptor-mediated cell growth inhibition. Mol Endocrinol 2008; 22: 2520-2530.
24. Festuccia C, Dondi D, Piccolella M, Locatelli A, Gravina GL, Tombolini V, Motta M,. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate 2010; 70: 1340-1349.
25. Zambrano A, Kalantari M, Simoneau A, Jensen JL, Villarreal LP,. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 2002; 53: 263-276. (Pubitemid 35398497)
26. DiPaolo JA, Popescu NC, Alvarez L, Woodworth CD,. Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. Crit Rev Oncog 1993; 4: 337-360.
27. Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR, Fisher C,. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J Virol 2004; 78: 9041-9050. (Pubitemid 39096515)
28. Leiros GJ, Galliano SR, Sember ME, Kahn T, Schwarz E, Eiguchi K,. Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol 2005; 24: 5-15.
29. Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S, Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, et al. Human papillomavirus 16, 18 and 33 infections and risk of prostate cancer: A Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005; 14: 2952-2955. (Pubitemid 43068830)
30. Prétet JL, Charlot JF, Mougin C,. Virological and carcinogenic aspects of HPV. Bull Acad Natl Med 2007; 191: 611-623.
31. Martinez-Fierro ML, Leach RJ, Gomez-Guerra L, Garza-Guajardo R, Pais-Johnson T, Beuten J, Morales-Rodriguez IB, Hernandez-Ordonez MA, Calderon-Cardenas G, Ortiz-Lopez R, et al. Identification of viral infections in the prostate and evaluation of their association with cancer. BMC Cancer 2010; 10: 326.
32. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET,. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12: 33-340.
33. Guarino M, Rubino B, Ballabio G,. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007; 39: 305-318. (Pubitemid 46897605)
34. Yuan TC, Veeramani S, Lin MF,. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14: 531-547. (Pubitemid 350074046)
35. Vindrieux D, Escobar P, Lazennec G,. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 2009; 16: 663-673.
36. Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM,. Senescence-associated exosome release from human prostate cancer cells. Cancer Res 2008; 68: 7864-7871.
37. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ,. Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-3374.
38. Nilsson BO, Carlsson L, Larsson A, Ronquist G,. Autoantibodies to prostasomes as new markers for prostate cancer. Ups J Med Sci 2001; 106: 43-49.
39. Mignot G, Roux S, Thery C, Ségura E, Zitvogel L,. Prospects for exosomes in immunotherapy of cancer. J Cell Mol Med 2006; 10: 376-388. (Pubitemid 44870186)
40. Utleg AG, Yi EC, Xie T, Shannon P, White JT, Goodlett DR, Hood L, Lin B,. Proteomic analysis of human prostasomes. Prostate 2003; 56: 150-161. (Pubitemid 41490332)
41. Savina A, Fader CM, Damiani MT, Colombo MI,. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic 2005; 6: 131-143.
42. Yu X, Harris SL, Levine AJ,. The regulation of exosome secretion: A novel function of the p53 protein. Cancer Res 2006; 66: 4795-4801.
43. Lanzetti L,. Actin in membrane trafficking. Curr Opin Cell Biol 2007; 19: 453-458. (Pubitemid 47268758)
44. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS,. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18: 1215-1223. (Pubitemid 28132513)
45. Degeorges A, Hoffschir F, Cussenot O, Gauville C, Le Duc A, Dutrillaux B, Calvo F,. Recurrent cytogenetic alterations of prostate carcinoma and amplification of c-myc or epidermal growth factor receptor in subclones of immortalized PNT1 human prostate epithelial cell line. Int J Cancer 1995; 62: 724-731.
46. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, Storto PD, Huard TK, Rhim JS, Williams DE,. A human prostatic stromal myofibroblast cell line WPMY-1: A model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 1999; 20: 1185-1192. (Pubitemid 29341437)
47. Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE,. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 2001; 47: 1-13. (Pubitemid 32246747)
48. Leira F, Alvarez C, Cabado AG, Vieites JM, Vieytes MR, Botana LM,. Development of a F actin-based live-cell fluorimetric microplate assay for diarrhetic shellfish toxins. Anal Biochem 2003; 317: 129-135. (Pubitemid 36577621)
49. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG,. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33753-33762. (Pubitemid 37553209)
50. Hall A,. Rho GTPases and the actin cytoskeleton. Science 1998; 279: 509-514. (Pubitemid 28067271)
51. Malacombe M, Ceridono M, Calco V, Chasserot-Golaz S, McPherson PS, Bader MF, Gasman S,. Intersectin-1L nucleotide exchange factor regulates secretory granule exocytosis by activating Cdc42. EMBO J 2006; 25: 3494-3503. (Pubitemid 44264860)
52. Yasuda S, Taniguchi H, Oceguera-Yanez F, Ando Y, Watanabe S, Monypenny J, Narumiya S,. An essential role of Cdc42-like GTPases in mitosis of HeLa cells. FEBS Lett 2006; 580: 3375-3380. (Pubitemid 43795903)
53. Martin-Belmonte F, Gassama A, Datta A, Yu W, Rescher U, Gerke V, Mostov K,. PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42. Cell 2007; 128: 383-397. (Pubitemid 46123512)
54. Dowal L, Provitera P, Scarlata S,. Stable association between G alpha(q) and phospholipase C beta 1 in living cells. J Biol Chem 2006; 281: 23999-24014. (Pubitemid 44274174)
55. Jezyk MR, Snyder JT, Gershberg S, Worthylake DK, Harden TK, Sondek J,. Crystal structure of Rac1 bound to its effector phospholipase C-beta2. Nat Struct Mol Biol 2006; 13: 1135-1140. (Pubitemid 44885926)
56. Golebiewska U, Scarlata S,. Galphaq binds two effectors separately in cells: Evidence for predetermined signaling pathways. Biophys J 2008; 95: 575-582.
57. Ueda H, Nagae R, Kozawa M, Morishita R, Kimura S, Nagase T, Ohara O, Yoshida S, Asano T,. Heterotrimeric G protein betagamma subunits stimulate FLJ00018, a guanine nucleotide exchange factor for Rac1 and Cdc42. J Biol Chem 2008; 283: 1946-1953.
58. Lopez-Ilasaca M,. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 1998; 56: 269-277. (Pubitemid 28473199)
59. Villanueva J, Yung Y, Walker JL, Assoian RK,. ERK activity and G1 phase progression: Identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 2007; 18: 1457-1463. (Pubitemid 46626640)
60. Klein EA, Campbell LE, Kothapalli D, Fournier AK, Assoian RK,. Joint requirement for Rac and ERK activities underlies the mid-G1 phase induction of cyclin D1 and S phase entry in both epithelial and mesenchymal cells. J Biol Chem 2008; 283: 30911-30918.
61. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M, Limonta P,. Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 1996; 81: 3930-3937. (Pubitemid 26380398)
62. Hu Y, Bowtell DD,. Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation. Oncogene 1996; 12: 1865-1872. (Pubitemid 26160070)
63. Sakaguchi K, Okabayashi Y, Kido Y, Kimura S, Matsumura Y, Inushima K, Kasuga M,. Shc phosphotyrosine-binding domain dominantly interacts with epidermal growth factor receptors and mediates Ras activation in intact cells. Mol Endocrinol 1998; 12: 536-543. (Pubitemid 30659084)
64. Shah BH, Farshori MP, Jambusaria A, Catt KJ,. Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation. J Biol Chem 2003; 278: 19118-19126. (Pubitemid 36799300)
65. Frödin M, Gammeltoft S,. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999; 151: 65-77.
66. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM,. The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136. (Pubitemid 120035062)
67. Passer BJ, Nancy-Portebois V, Amzallag N, Prieur S, Cans C, Roborel de Climens A, Fiucci G, Bouvard V, Tuynder M, Susini L, et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc Natl Acad Sci USA 2003; 100: 2284-2289. (Pubitemid 36297491)
68. Terrano DT, Upreti M, Chambers TC,. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol Cell Biol 2010; 30: 640-656.